Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001) Meeting Abstract


Authors: Riely, G. J.; Kris, M. G.; Schwartz, L. H.; Akhurst, T.; Zhao, B.; Milton, D. T.; Moore, E.; Tyson, L.; Pao, W.; Miller, V. A.
Abstract Title: Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001)
Meeting Title: 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 24
Issue: 18 Suppl. Pt. 1
Meeting Dates: 2006 Jun 2-6
Meeting Location: Atlanta, GA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2006-06-01
Start Page: 380S
Language: English
ACCESSION: WOS:000239009402391
PROVIDER: wos
Notes: --- - Meeting Abstract: 7065 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology - JUN 02-06, 2006 - Atlanta, GA - S - Part 1 - "Source: Wos"